[3H](-)CGP12177   Click here for help

GtoPdb Ligand ID: 531

Synonyms: [3H](-)CGP 12177
 Ligand is labelled  Ligand is radioactive
Compound class: Synthetic organic
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 3
Hydrogen bond donors 4
Rotatable bonds 6
Topological polar surface area 90.14
Molecular weight 279.16
XLogP 0.62
No. Lipinski's rules broken 0

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

SMILES / InChI / InChIKey
Click here for help
Canonical SMILES OC(COc1cccc2c1[nH]c(=O)[nH]2)CNC(C)(C)C
Isomeric SMILES O[C@H](COc1cccc2c1[nH]c(=O)[nH]2)CNC(C)(C)C
InChI InChI=1S/C14H21N3O3/c1-14(2,3)15-7-9(18)8-20-11-6-4-5-10-12(11)17-13(19)16-10/h4-6,9,15,18H,7-8H2,1-3H3,(H2,16,17,19)/t9-/m0/s1
InChI Key UMQUQWCJKFOUGV-VIFPVBQESA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

References
1. Baker JG. (2005)
Evidence for a secondary state of the human beta3-adrenoceptor.
Mol Pharmacol, 68 (6): 1645-55. [PMID:16129733]
2. Baker JG. (2005)
The selectivity of beta-adrenoceptor antagonists at the human beta1, beta2 and beta3 adrenoceptors.
Br J Pharmacol, 144 (3): 317-22. [PMID:15655528]
3. Baker JG. (2010)
The selectivity of beta-adrenoceptor agonists at human beta1-, beta2- and beta3-adrenoceptors.
Br J Pharmacol, 160 (5): 1048-61. [PMID:20590599]
4. Baker JG. (2026)
Comparing the Molecular Pharmacological Properties of Existing β-Blockers to Determine the Theoretically Most "Ideal" Anti-Cancer β-Blocker.
Pharmacol Res Perspect, 14 (1): e70214. [PMID:41485077]
5. Baker JG, Gardiner SM, Woolard J, Fromont C, Jadhav GP, Mistry SN, Thompson KSJ, Kellam B, Hill SJ, Fischer PM. (2017)
Novel selective β1-adrenoceptor antagonists for concomitant cardiovascular and respiratory disease.
FASEB J, 31 (7): 3150-3166. [PMID:28400472]
6. Baker JG, Hall IP, Hill SJ. (2002)
Pharmacological characterization of CGP 12177 at the human beta(2)-adrenoceptor.
Br J Pharmacol, 137 (3): 400-8. [PMID:12237261]
7. Baker JG, Proudman RG, Hawley NC, Fischer PM, Hill SJ. (2008)
Role of key transmembrane residues in agonist and antagonist actions at the two conformations of the human beta1-adrenoceptor.
Mol Pharmacol, 74 (5): 1246-60. [PMID:18687809]
8. Baker JG, Proudman RG, Hill SJ. (2013)
Impact of polymorphic variants on the molecular pharmacology of the two-agonist conformations of the human β1-adrenoceptor.
PLoS One, 8 (11): e77582. [PMID:24250787]
9. Baker JG, Proudman RG, Hill SJ. (2015)
Salmeterol's extreme β2 selectivity is due to residues in both extracellular loops and transmembrane domains.
Mol Pharmacol, 87 (1): 103-20. [PMID:25324048]
10. Lim VJY, Proudman RGW, Monteleone S, Kolb P, Baker JG. (2023)
The Isoleucine at Position 118 in Transmembrane 2 Is Responsible for the Selectivity of Xamoterol, Nebivolol, and ICI89406 for the Human β1-Adrenoceptor.
Mol Pharmacol, 103 (2): 89-99. [PMID:36351797]